Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio The Cluster of Differentiation (CD) 3 is a receptor on ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
DURHAM, N.C., NEW YORK & LONDON--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback